No Data
No Data
Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q4 2024 Earnings Conference
The following is a summary of the Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript:Financial Performance:Reported a significant reduction in R&D expenses to $20 million for FY 2024
VistaGen Therapeutics | 10-K: Annual report
VistaGen Therapeutics GAAP EPS of -$1.52 Misses by $1.16, Revenue of $1.06M Beats by $0.86M
Vistagen Reports FY24 Net Loss Of $(29.4)M Vs $(59.2)M Last Year
Cash and cash equivalents were $119.2 million as of March 31, 2024.
Express News | Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update